Equity Research, Broker Reports, and media content on Consort Medical

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Consort Medical
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login
  • 21 Oct 19

Quarterly Research Outlook Autumn 2019

Following continued delays of a Brexit agreement, few sectors within the UK market have remained attractive to investors despite low valuations. One sector which has continued to outperform despite the political drama has been the UK video gaming sector (henceforth UK gaming), which we are fans of. We believe a combination of sector-leading growth, strong cash conversion and timely cyclical positioning support our positive view on the UK video gaming sector.

Companies: ABBY AMS ANX ARS ATYM AVON BLVN PIER BUR CGS CAML CDM CSRT TIDE CYAN DTG DEMG ELM EMR FPO FDEV GTLY GENL GHH GRI GEEC GKP HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KAPE KEYS KWS KCT KGH LAM LIT LOK MACF MANO MOD OXIG PCA PANR APP SRE PHC PMO RBW RMM RBGP REDD RSW RNO ROR SUS SCPA SEN SHG SOLG SOM SUMO TM17 INCE TWD TRAK TRI VNET VTC ZOO ZTF

  • 23 Jul 19

Quarterly Research Outlook - Summer 2019

In January, we provided a list of 11 stocks for 2019 that we believed would perform strongly with attractive catalysts that could lead to material outperformance. In this Quarterly Research Outlook, we revisit these views, analysing what has happened and how the remaining six months of the year could play out.

Companies: AMS ANX ARS ATYM AVON BLVN PIER BUR CGS CAML CALL CSRT TIDE CYAN DTG DEMG ELM EMR FPO FST GTLY GENL GRI GEEC GKP HMI HAYD HEAD HILS HTG HUR HYR IBPO IOG INDI JHD JOG KAPE KEYS KCT KGH LAM LIT LOK MACF MANO PCA PANR PXC PHC PMO RBW RMM REDD RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG SOM TWD TRAK TSG TRI VNET VTC ZOO ZTF

  • 11 Apr 19

Quarterly Research Outlook

We’re just over three months in to 2019 and we’ve seen a 10% UK market rally, retracing much of the Q4 decline, such is the nature of fickle market sentiment. That said, many of the issues we wrote about three months ago that were impacting markets remain: notably Brexit, trade wars, geopolitics and global monetary policy. The 2019 rally thus far feels somewhat fragile, with competing forces of optimism on a potential trade deal which could underpin the rally, against the deterioration in underlying economic data that could ultimately undermine the recent market gains. In this context, we look at what the lead indicators and the market are telling us about the industrial cycle and the stocks most exposed to various industrial trends. The Q4 derating in short cycle industrials and autos had been vicious and while these sectors have seen a more solid footing in 2019, with earnings downgrades being priced in, it will likely take a trough in lead indicators before short cycle stocks can start to perform again and re-rate relative to the market.

Companies: ARS CYAN HYR LIT SOM ABBY AMS AMER ANX ATYM AVON BLVN PIER BUR CGS CAML CALL CSRT TIDE DTG DEMG EMR FPO FST GTLY GENL INCE GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO INDI JHD JOG KEYS KCT KGH LAM LOK MACF MNO MANO MOD MKLW OXIG PCA PANR APP PXC PHC PMO RBW RMM REDD RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG TRAK TRI VNET VTC ZOO ZTF

  • 01 Feb 19

Most popular equity research this week | 28 Jan - 1 Feb

See what's trending this week...

Companies: MODWJAARSATYMALHVSAVONCSRTCGSTIDEELMFPOHEADHILSHTGAMSMACFMKLWOXIGAPPSCPARSWRNOSUSKCTTRIVTCIQEZTFDEMGEMRBLVNGRIRMMHDYSHGRKHJHDTRAKSOLGVNETDTGLAMZOOPMOCALLHURCAMLANXIOGPCARBGPKGHTWDPIERHAYDREDDFLO7DIGSPERORGTLYW7LJOGPRSMKEYSINDIIBPORBWABBYGENLFSTGEEC
  • 31 Jan 19

Quarterly Research Outlook

The market has not faced quite so many conflicting challenges for a number of years, whether related to global geopolitics, trade wars, ongoing Eurozone issues or the “will they, won’t they” saga of Brexit. In our Best Ideas, we sought to highlight stocks that present investors with interesting opportunities following recent market moves. Those stocks, we believe, warrant investor attention, in many cases for uncorrelated or stockspecific reasons, regardless of the near-to-medium term market direction. These stocks, in general, represent attractive and well-managed businesses or assets, with share price catalysts and where valuations or recent stock performance provide investors with a good entry point.

Companies: 7DIG ABBY AMS ANX ARS ATYM AVON BLVN PIER CGS CAML CALL CSRT TIDE DTG DEMG ELM EMR FPO FST GTLY GENL GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KEYS KCT KGH LAM MACF MOD MKLW OXIG PCA APP PMO RBW RMM REDD RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG TWD TRAK TRI VNET VTC ZTF

  • 03 Nov 18

Most popular equity research this week | 22 Oct - 2 Nov

See what's trending this week...

Companies: HMIARSATYMAVONCSRTCGSTIDEELMFPOHEADHILSHTGAMSMACFMKLWOXIGAPPSCPARSWRNOSUSTRIVTCZTFDISWMHAMERFPMDEMGEMRBLVNGRIRMMHDYCKTSHGSXXRKHJHDTRAKSOLGPHDVNETDTGLAMPDGCALLHURCAMLAREANXIOGPCARBGPKGHTWDPIERHAYDREDDCAKENAH7DIGRORGTLYW7LJOGMNOKEYSGYGINDIIBPORBWABBYFLTRGVCGENLSFEFSTGEEC
  • 23 Oct 18

Quarterly Research Outlook

The June IPO of Knights Group Holdings, a Top-100 regional law firm, marked the fifth entrant to the burgeoning UK-listed legal sector. Following recent expansion of our coverage across all five listed legal firms, complemented by coverage of three broader support services peers with exposure to the sector, we revisit and build upon our views on this rapidly evolving sector.

Companies: ARS GTLY GENL KEYS KGH MNO RBGP TWD 7DIG ABBY AMS AMER ANX ARS ATYM AVON BLVN PIER CGS CAML CALL CSRT TIDE DTG DEMG ELM EMR FPM FPO FST GTLY GENL GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KEYS KGH LAM MACF MNO MKLW NAH OXIG PCA APP CAKE PDG RBW RMM REDD RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG TWD TRAK TRI VNET VTC ZTF

  • 20 Jul 18

Most popular equity research this week | 16 - 20 July

See what's trending this week...

Companies: HMIAPCAVONCSRTCGSTIDEELMFPOHEADHILSHTGAMSMACFMPACMKLWOXIGAPPSNXSCPARSWRNOSUSKCTTRIVTCZTFFPMDEMGAMOEMRBLVNHDYBGOSHGRKHJHDTRAKDTGLAMPDGCALLHURIOGPCAEUSPCDMPIERLSAIHAYDFDMREDDCAKENAHSPERORGTLYECSCGETBFUTRINCEINDIIBPORBWABBYKETLJELGENLABCBGEEC
  • 18 Jul 18

Quarterly Research Outlook

In Q2, UK equities regained some of their poise after the draw down in Q1, although uncertainty around Brexit continued to grab the headlines. On the back of this, investor concern about the UK economy has been understandable in recent months given a number of negative data points. However, we see reasons for optimism for UK Plc with wage growth supporting an improving outlook for the consumer and business investment holding up. That said, continuing UK political disruption clearly remains a risk going forward.

Companies: AMER EMR HMI JOG PDG ABBY AMS AVON BLVN PIER CGS CALL CSRT TIDE DTG DEMG ELM EMR FPM FPO GTLY GENL INCE GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG LAM MACF MKLW NAH OXIG PCA APP CAKE PDG RBW REDD RSW RNO RKH ROR SUS SCPA SHG KCT TRAK TRI VTC ZTF

  • 14 Jun 18

Morning Song

1Spatial (SPA LN) Capital markets day highlights growth potential | Abzena (ABZA LN) Monetising the Abzena Inside portfolio | Consort Medical (CSRT LN) Prelims in line – another setback with Mylan | Gym Group (GYM LN) Positive corporate and premium pricing newsflow | N Brown Group (BWNG LN) In line update but number of moving parts might leave investors cold | Rathbone Brothers (RAT LN) Acquisition of Speirs & Jeffrey, no EPS accretion until FY20e | RhythmOne (RTHM LN) FY18 results show execution, EBITDA to almost quadruple in FY19 | Speedy Hire (SDY LN) Recovery delivered; Returns improving

Companies: ABZA CSRT GYM BWNG RAT RTHM SDY SPA

  • 07 Mar 18

Structural growth in a complex landscape

Pharmaceutical Services is a vast and varied landscape, reflecting the complexities in the discovery, development, manufacturing and monitoring of drugs and devices, all within a stringent regulatory environment. The overall growth prospects are highly favourable: drug development activity globally is on the up, led by smaller companies, which is driving demand for outsourced services. In this report we provide a breakdown of the sector into its main activity segments, and identify biologics, increasing service specialisation and consolidation as important value drivers. Finally, we present 15 companies (9 of which are publicly listed) that, in our view, are well placed to benefit from the sector’s secular growth trends.

Companies: ABZA BQE CSRT INS UDG CLIN ABZA HZD ERGO OXB

  • 05 Dec 17

N+1 Singer - Consort Medical - In line interims, still waiting for a catalyst

Interims are in line. Revenues +6.1% reported, PBT+7.7% but adj EPS was only up 3.2% and Net Debt is still high at £97.1m. There is no new news on Mylan contract for generic Advair and we do not expect to hear anything until mid-2018. A couple of small contracts have drifted away. We make only minor changes to our estimates and don’t see any catalysts in the short term. The shares now trading on 17.7x P/E to Apr-18, 12.4x EV/EBITDA - not obviously cheap without growth picking up but maybe there is enough promise on the Mylan contract to keep people interested for now. We move to Hold from Buy.

Companies: Consort Medical
  • 20 Oct 17

Most popular equity research this week | 16 - 20 Oct

See what's trending this week...

Companies: WJASEEPLIFARNCSRTBTGAMSPHTMSYMDPHLGTEKFANCRRGDIMMAGYTSTLCTHBOTBDOTDVERBVXPSCLPABCFULDNLVLGHZDVECSHOECAKEC4XDSCSMTPHIDPRBGFISHHOTCJOULHCMMXCT
  • 10 Aug 17

Most popular equity research this week | 7 - 11 Aug

See what was trending this week...

Companies: PLISQSFARNCSRTBTGCTOAMSLGENSNXSUSDPHFA/EKFANCRIMMAGYCTHVERSPHRSCLPABCCNEKWSEVRHDNLBBSNEUSPVLGHZDFDMC4XDMTPHECSCPLUSTRMRHCMMXCTPPIXQRT
  • 15 Jun 17

N+1 Singer - Consort Medical - FY results in line with expectations; reiterate Buy

Today’s FY results are in line with our expectations, highlighting an improving operating performance at Aesica. The core Bespak delivered an in-line performance, impacted as expected by the termination of the supply agreement with Nicovations. We reiterate our Buy recommendation (upgraded from Hold in December 2016) and 1,125p target price.

Companies: Consort Medical

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Consort Medical. We currently have 60 research reports from 7 professional analysts.

Open
N/A
Range Today
N/A
52 Week
700/1075p
Daily Volume
N/A
# Shares
49.4m
Daily Liquidity
(0.07%)
Pension Liability
£44.5m
Enterprise Value
£467.6m
Market Cap
£523.3m
Latest PE (hist)
11.82
Div Yield
2.85

Latest News/RNS

(more news)
Date Source Announcement
06Dec19 07:00 RNS Publication of Offer Document
04Dec19 13:03 RNS Holding(s) in Company
03Dec19 07:00 RNS Interim Results
28Nov19 14:32 GNW Invesco Ltd.: Form 8.3 - consort medical plc
27Nov19 16:18 RNS Holding(s) in Company
26Nov19 07:00 RNS Update on Recipharm rights issue participation
25Nov19 08:00 RNS Notice of Results
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Consort Medical

  • Providers covering

    Consort Medical

  • 02 Dec 19

Acquisition – 7% accretive in first full year

SDI has announced the acquisition of Chell Instruments; paying c.£4.3m for the business (FY 2018 EV/Sales and EV/EBIT of 0.9x and 5.5x) funded from cash and a new debt facility with net debt at year-end now expected to be c.£5.0m. SDI has shown that it can source and execute another accretive acquisition in what was a competitive tender bid process. We expect the acquisition to be c.7% accretive to EPS in FY 2021 and raise our target price by 25% to 75p to reflect the accretion as well as rolling forward our target year, implying an EV/EBITDA of 11.9x and adjusted P/E of 17.3x.

Companies: Scientific Digital Imaging
  • 04 Dec 19

Cenkos: IXICO Plc -- Revenues growing and profitable

IXICO has reported a strong financial performance for FY19A built on continued commercial focus and a strengthened organisation. Revenues of £7.6m were up 40% and gross margin was up 600bps versus FY18A and the company delivered its first year of profitability since IPO. EBITDA of £0.5m was strongly ahead of our forecast (+£0.1m) and delivered an EBITDA margin of 6%. We have maintained our revenue growth expectations of 20% for FY20E and FY21E but have upgraded our profit expectations given the strong reported performance. We maintain our Buy recommendation.

Companies: IXICO
  • 02 Dec 19

Cenkos: Creo Medical Group Plc - Cutting edge

Creo Medical continues to make strong progress on both development and commercial fronts. Following its direct entry into the US, the company recently reported its first commercial revenues from that market, building upon the broad commercial reach developed via its signed-up distributor network. While lead product, Speedboat, is making commercial progress, Creo expects to launch a further four endoscopic instruments on the CROMA Advanced Energy platform during 2020, significantly expanding the utility of the generator. To maintain this momentum, Creo Medical has announced it has conditionally raised £43m via an equity placing and will supplement this via an open offer to qualifying shareholders. We maintain our Buy recommendation.

Companies: Creo Medical Group
  • 06 Dec 19

H1 results: adjustments to clinical programmes

ReNeuron has announced its H1 2020 results; financials are slightly ahead of our expectations related to the identified slower recruitment of the Phase III PISCES trial. ReNeuron has made a number of positive clinical trial protocol changes to both the CTX and hRPC programmes to boost enrolment and accelerate clinical development, respectively, and we have included these changes into our forecasts.

Companies: Reneuron Group
  • 03 Dec 19

SP Angel Healthcare Conditions

Collagen Solutions (COS.L): Interim results | Genedrive plc (GDR.L): Hearing loss assay kit demonstrates high clinical accuracy

Companies: Collagen Solutions Genedrive

  • 05 Dec 19

US licensing deal: Major Opportunity Within LupuzorTM Unlocked

ImmuPharma announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals (“Avion”), a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps). Avion has exclusively in-licensed LupuzorTM for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed. We have always believed that ImmuPharma could deliver such a successful deal for the US market (given the track record of the previous deal executed with Cephalon). This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of LupuzorTM. We now see LupuzorTM as having the ability to generate blockbuster sales in the US (US$1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of US$170m per year. What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for LupuzorTM but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for LupuzorTM, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment. This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of LupuzorTM, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa. Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 76p to 100p / share. BUY.

Companies: ImmuPharma
  • 05 Dec 19

Avacta Group - Executive interview

In this video, Alastair Smith, CEO of Avacta Group, discusses the progress the company has made this year. This includes new and expanded partnerships, operational and financial achievements, and the advancement of AVA6000 towards the clinic.

Companies: Avacta Group
  • 28 Nov 19

LIBERUM: Futura Medical* - December data could be game-changing

Futura is set to report headline data from its P3 FM57 study in erectile dysfunction (ED) in December. We believe that the trial is significantly de-risked and hence estimate a >70% probability of some form of positive outcome.

Companies: Futura Medical
  • 04 Dec 19

Proving the accuracy and superiority of minibeams

The goal of Advanced Oncotherapy (AVO) is to deliver an affordable and more effective proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked through important technical milestones. AVO is now working on the verification and validation phase, prior to CE marking and LIGHT being used on the first patients. Meanwhile, AVO has entered into a research collaboration with the Cleveland Clinic aimed at proving the accuracy of targeting cancerous tissue, and sparing normal tissue, with proton minibeams in comparison with other methodologies.

Companies: Advanced Oncotherapy
  • 18 Jul 19

FY results; acquisitions to fully benefit FY 2020

Full-year results to 30 April 2019 were in line at the revenue line but 5% (£0.1m) better than expected at the adjusted pre-tax profit level. Underpinned by c.5.5% organic growth, the 20% and 26% increases in revenue and adjusted EBITDA were driven by full-year contributions from ATC and QSI, acquired in FY 2018, as well as five acquisitions in FY 2019. Notable was the 35% increase in free cashflow. Additional investments into Sentek, Atik, Graticules and Astles and the integration of ATC with Thermal Exchange in FY 2020 should benefit the businesses in FY 2021. We upgrade our FY 2020 adjusted EPS by 7% as well as introduce FY 2021 forecasts, which indicate 13% EPS growth. The company indicates that it expects to add at least one new business in FY 2020, which will be incremental to these forecasts. We are raising our target price by 9% to 60p, reflecting the improved gross margins and stronger underlying cashflow.

Companies: Scientific Digital Imaging
  • 02 Dec 19

Interims – VISITECT CD4 starts to deliver on potential

Interim results were in line with the 22 October trading update, reflecting the financial benefits of closing its German business and selling the infectious disease business. Revenues from continuing operations increased 6% to £4.5m, largely reflecting the growth in Food Intolerance (+6% to £4.1m). This resulted in an adjusted EBITDA and pre-tax loss of c.£0.25m (vs. -£0.3m) and c.£0.35m (vs. -£0.5m), respectively. Omega also announced a further order from Nigeria for VISTECT CD4, which is contingent on approval in that market, but could be shipped by the FY year-end. We are not changing CD4 forecasts at this time until there is clarity over MoH approval. We make minor changes, however, to our FY forecasts to reflect the adoption of IFRS 16, which reduces adjusted pre-tax profits by c.£60k in both years. Year-end net debt is unchanged at c.£0.8m. We leave our target price unchanged at 25p.

Companies: Omega Diagnostics Group
  • 03 Dec 19

Cenkos: Collagen Solutions Plc -- Continued momentum

Collagen Solutions has reported results for the six-months to September 2019 (H1/20). As announced with the October Trading Update, revenues grew 14.4% to £2.23m for the period. Revenues were driven by the Core business which delivered 56% growth. The business acquired four new contracts and ten new customers during the period. The company remains engaged with its notified body in relation to ChondroMimetic, with the changing medical device regulatory environment limiting visibility on the timing of approval. We maintain our Buy recommendation.

Companies: Collagen Solutions
  • 28 May 19

Disease Modification in a Spectrum of Severity for Lupus Patients

ImmuPharma is a European, late-stage biotechnology company, focused on delivering major new autoimmune therapies. It is developing the novel drug LupuzorTM (forigerimod) a first-in-class autophagy modulator, a late-stage asset with blockbuster potential, that has already shown itself to be safe across multiple trials in what now amounts to hundreds of lupus (Systemic Lupus Erythematosus, SLE) patients. The drug (LupuzorTM) was previously licensed to Cephalon (now Teva) for US$45m (upfront and option), US$500m in potential milestones and a high double-digit royalty stream before regaining global rights. The heterogeneity of lupus disease can be viewed as a spectrum of severity in patients, thus identifying and classifying the disease itself, opens up the opportunity for ImmuPharma to pivot and drive towards a precision-medicine biomarker approach and to provide a stratified disease approach that could help to improve healthcare economics for payors. We initiate with a BUY rating based on what we believe are strongly oversold shares and a target price of 92p.

Companies: ImmuPharma
  • 09 Jul 19

Rare ‘hi-growth disrupter’ at modest price

Given the S&P500 is within a whisker of all-time highs, it is virtually impossible to find undervalued, high quality, growth stocks - especially those possessing ‘disruptive’ technology and addressing $bn end-markets. However we think Kromek, a leading next generation radiation detection business, is one. Today it posted FY19 turnover up 22.6% LFL to £14.5m (vs £11.8m LY), alongside a 4-fold increase in EBITDA (pre SBPs) to £2.0m (£0.5m). Better still momentum accelerated throughout the period, with H2’19 EBITDA coming in at £2.5m (margin 23.3%) on sales of £10.8m (£7.0m LY).

Companies: Kromek Group
  • 11 Jul 19

Diversification and scale for online success

The global online gaming market generated c £40bn of gross gaming revenues (GGR) in 2018 and newly regulating markets (the US) are expected to contribute to 7% CAGR to 2023 (according to H2 Gambling Capital (H2GC)). However, while regulated markets have provided significant opportunities for operators to date, government intervention remains a constant threat and legislation is tightening. Some mature markets (notably the UK) have been raising taxes and implementing regulatory burdens, which increases the cost of business. In our view, success will depend on a combination of scale, diversification, proprietary technology and a strong balance sheet. Many of the 12 operators in this report should benefit from these dynamics and sector valuations remain attractive, at 12.6x P/E, 8.2x EV/EBITDA and 6.0% dividend yield for FY19.

Companies: 888 ACX BETSB ORPH GVC GYS OPAP PTEC RNK WMH